Geoffrey Meacham J.P. Morgan
In second place for a third straight year, Geoffrey Meacham keeps probing deep into the small- and midcap universe to come up with what one approving J.P. Morgan client calls “good, actionable, out-of-the-box trading opportunities.” One example: neurology drug developer Acorda Therapeutics of Hawthorne, New York. Meacham first recommended the stock way back in March 2008 and has highlighted the call repeatedly since, most recently in February, at $29.09. The share price rose as high as $39.70 in May before drifting back down, ending August at $30.12, but the analyst remains bullish. Investors who bought the stock when Meacham first recommended it enjoyed a 67.5 percent gain, through August 2010.